- Home
- FURY vs KZIA Comparison
FURY vs KZIA Comparison
Compare FURY & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FURY | KZIA |
|---|---|---|
| Founded | 2008 | 1994 |
| Country | Canada | Australia |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 100.8M |
| IPO Year | 2011 | 2002 |
Fundamental Metrics
Financial Performance| Metric | FURY | KZIA |
|---|---|---|
| Price | $0.57 | $13.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $1.70 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 346.9K | 259.0K |
| Earning Date | 08-11-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $3.05 |
| 52 Week High | $1.02 | $17.40 |
Technical Indicators
Market Signals| Indicator | FURY | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 40.32 | 77.03 |
| Support Level | $0.51 | $5.85 |
| Resistance Level | $0.64 | $14.42 |
| Average True Range (ATR) | 0.03 | 1.29 |
| MACD | -0.00 | 0.25 |
| Stochastic Oscillator | 18.50 | 99.81 |
Price Performance
Historical ComparisonAbout FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.